Pfizer sets sights on Summit’s bispecific in combo with its ADCs
Pfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s ivonescimab in combination with several of its ADCs.
Pfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s ivonescimab in combination with several of its ADCs.
What's Your Reaction?
